BridgeBio (BBIO.US) cardiovascular therapy acoramidis shows better real-world performance than Pfizer (PFE.US) competing drug
智通财经2026/09/24 00:46Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Zhihu Finance APP has learned that BridgeBio Pharma (BBIO.US) announced on Wednesday that its cardiac therapy acoramidis (U.S. brand name Attruby) outperformed Pfizer’s (PFE.US) competing drug tafamidis (U.S. brand name Vyndamax) in a real-world study.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Crypto prices
More
Bitcoin
BTC
$84,118.34
-2.77%
Ethereum
ETH
$2,687.42
-2.63%
Tether USDt
USDT
$0.9998
-0.00%
BNB
BNB
$773.22
-2.39%
XRP
XRP
$1.51
-6.23%
USDC
USDC
$0.9999
-0.01%
Solana
SOL
$115.12
-2.81%
TRON
TRX
$0.3433
-0.12%
Zcash
ZEC
$1,519.72
-6.08%
Hyperliquid
HYPE
$92.64
-4.78%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now